Contact
searchSearch
HMP Global

Hemophilia Topic Center

News
New siRNA Shows Long-Term Efficacy and Enhanced Safety in Hemophilia A and B
04/21/2025
Grace Taylor, MS, MA
A long-term study reveals that fitusiran effectively rebalances hemostasis while reducing bleeding episodes in patients with hemophilia.
A long-term study reveals that fitusiran effectively rebalances hemostasis while reducing bleeding episodes in patients with hemophilia.
A long-term study reveals that...
04/21/2025
First Report Managed Care
News
Bone Health Screenings Underused in US Hemophilia Centers Despite High Risk
04/17/2025
Grace Taylor, MS, MA
Low screening rates for osteoporosis in people with hemophilia highlight a critical gap in preventative care at US federally funded hemophilia centers.
Low screening rates for osteoporosis in people with hemophilia highlight a critical gap in preventative care at US federally funded hemophilia centers.
Low screening rates for...
04/17/2025
First Report Managed Care
News
Fitusiran Shows Sustained Bleed Control and Safety With AT-Guided Dosing in Hemophilia
04/14/2025
Juliet Gallagher
Findings from a phase 2 open-label extension study suggest that fitusiran, a small interfering RNA (siRNA) therapy targeting antithrombin (AT), offers sustained bleeding control and quality of life improvements in people with moderate or...
Findings from a phase 2 open-label extension study suggest that fitusiran, a small interfering RNA (siRNA) therapy targeting antithrombin (AT), offers sustained bleeding control and quality of life improvements in people with moderate or...
Findings from a phase 2...
04/14/2025
First Report Managed Care
News
Maximizing Factor VIII to Reduce Costs and Complications in Hemophilia A
04/09/2025
Juliet Gallagher
A recent supplement published in The American Journal of Managed Care explores the ongoing clinical and economic challenges in hemophilia A care, with a specific focus on optimizing factor VIII (FVIII) levels through prophylaxis, personalized...
A recent supplement published in The American Journal of Managed Care explores the ongoing clinical and economic challenges in hemophilia A care, with a specific focus on optimizing factor VIII (FVIII) levels through prophylaxis, personalized...
A recent supplement published in...
04/09/2025
First Report Managed Care
News
Advances in Factor IX Therapy Offer New Hope for Hemophilia B Treatment
10/23/2024
Lisa Kuhns, PhD, MD
New factor IX therapies promise improved treatment for hemophilia B.
New factor IX therapies promise improved treatment for hemophilia B.
New factor IX therapies promise...
10/23/2024
First Report Managed Care
News
New Guidance Addresses Management of Patients With Congenital Hemophilia
10/09/2024
Jolynn Tumolo
New guidelines from the International Society on Thrombosis and Haemostasis strongly recommend prophylactic treatment over episodic for patients with severe and moderately severe hemophilia A and B, with conditional recommendations for other...
New guidelines from the International Society on Thrombosis and Haemostasis strongly recommend prophylactic treatment over episodic for patients with severe and moderately severe hemophilia A and B, with conditional recommendations for other...
New guidelines from the...
10/09/2024
First Report Managed Care
News
Investigational 4F-PCC Non-Inferior to Control for Vitamin K Antagonist Reversal
09/23/2024
Jolynn Tumolo
An investigational 4-factor prothrombin complex concentrate (4F-PCC) was hemostatically non-inferior to a licensed control 4F-PCC for the rapid reversal of vitamin K antagonists (VKA) in patients needing urgent surgery, according to study...
An investigational 4-factor prothrombin complex concentrate (4F-PCC) was hemostatically non-inferior to a licensed control 4F-PCC for the rapid reversal of vitamin K antagonists (VKA) in patients needing urgent surgery, according to study...
An investigational 4-factor...
09/23/2024
First Report Managed Care
News
HAVEN 7 Trial Evaluates Emicizumab Prophylaxis in Infants With Hemophilia A
06/19/2024
Grace Taylor, MS, MA
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy,...
06/19/2024
First Report Managed Care
News
Factor VIII Market Expected to Grow Over Next 5 Years
05/24/2024
Jolynn Tumolo
The global market for human coagulation factor VIII, which holds significant importance in managing hemophilia A, is poised for substantial growth over the coming years, according to market research firm Quants and Trends.
The global market for human coagulation factor VIII, which holds significant importance in managing hemophilia A, is poised for substantial growth over the coming years, according to market research firm Quants and Trends.
The global market for human...
05/24/2024
First Report Managed Care
News
Study Finds No Treatment-Related Adverse Events in Boys Treated With Purified FIX Concentrate
05/09/2024
Jolynn Tumolo
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX)...
05/09/2024
First Report Managed Care
Industry Insights
News
Expert Perspectives
Podcasts
FRMC Volume 22, Issue 1

Current Issue

March 2025
Volume 22
Issue 1
Current Issue
Issue Archive

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use